Regulatory Expansion The Corvia Atrial Shunt is approved in Europe for HFpEF/HFmrEF but is investigational in the US. This opens sales opportunities around clinical trial site development, investigator-initiated studies, and regulatory liaison with major health systems and academic centers preparing for future commercialization.

Evidence-driven Sales Leverage clinical data from the REDUCE LAP-HF II trial and related publications to build a compelling value proposition for HF programs, interventional cardiology labs, and academic centers, supporting patient selection criteria, enrollment recruitment, and payer discussions.

Funding Momentum A strong investor syndicate and ongoing funding activity create capacity to accelerate trial expansion, field team deployment, and strategic partnerships, including potential distribution or co-development with established medtech players.

Target Segments Focus on HF clinics, advanced heart failure programs, and interventional labs where elevated left atrial pressures during exercise are prevalent; pursue payer pilots and early access discussions to pave reimbursement pathways.

Differentiation & Partnerships Capitalize on the remote monitoring collaboration with PhysIQ to offer data-driven post-implant monitoring and AI insights; position against competition like LimFlow by emphasizing this integrated data capability and potential co-development or distribution partnerships with large medtech players.